BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing dolutegravir (Tivicay®, Triumeq®, Juluca®): neural tube defects in babies whose mothers became pregnant while taking dolutegravir

2018.06.04

Active substance: dolutegravir

There are reports from an observational study on neural tube defects in babies, whose mothers became pregnant while taking dolutegravir.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 510KB, File is accessible